C
Cheiron
AI-native operating system for drug programs
About Cheiron
Cheiron (PhnyX Lab Inc.) is building an AI-native operating system for drug programs that models the live state of a therapy—claims, evidence, assumptions, risks, decisions and commitments—as a connected system rather than scattered papers, trials and institutional memory. At the center is its Life Sciences Knowledge Graph (LKG), linking biomedical, clinical, regulatory, patent and commercial knowledge for inferences such as trial design versus regulatory precedent or contradictions between competitor data and patents. In July 2026 Cheiron announced an $8 million seed led by Menlo Ventures, with strategic support from industry figures including Moderna co-founder Robert Langer, former Pfizer CMO Freda Lewis-Hall, Chai Discovery CEO Josh Meier and former Starbucks CEO Laxman Narasimhan, to accelerate the Knowledge Graph, expand clinical/regulatory/strategic workflows and grow engineering, product and life-sciences teams. Sources: Cheiron blog 23 Jul 2026.
Source: Dealroom company dataAt a glance
- Founded
- 2024
- Headquarters
- Los Altos, United States
- Sector
- Health
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
SK Networks
Illia Polosukhin
Aidan Gomez
Menlo Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cheiron on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cheiron on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.